DOCK2 factors in the capacity of Wnt5a to enhance CLL proliferation. (A) CLL cells from each of 6 patients (3 U-CLL and 3 M-CLL) transfected with control siRNA or siRNA targeting DOCK2 and examined 72 hours later by western blot. Data are shown as mean ± SD (n = 6). Cell viability was examined more than 80% both in control or DOCK2-siRNA transfected cells. (B) Fluorescence of CLL cells stained with carboxyfluorescein diacetate succinimidyl ester and treated with CD154, without (−) or with (+) Wnt5a. The percentage of dividing cells is indicated in each histogram. (C) Mean proportions of dividing CLL cells from each of 6 patients (3 U-CLL and 3 M-CLL) under conditions indicated at the bottom. P < .05; P < .01; P < .001, as assessed by 2-tailed Student t test. (D) CLL cells transfected 72 hours previously with control siRNA or siRNA targeting DOCK2. Cell viability was higher than 80% both in control or DOCK2-siRNA transfected cells. CLL cell migration in response to CXCL12 (200 ng/mL) was assessed without (−) or with (+) addition of exogenous Wnt5a (200 ng/mL), as indicated at the bottom. Data are shown as mean ± SD from 3 independent experiments of CLL cells from each of 6 patients (3 U-CLL and 3 M-CLL). P < .05; P < .001, as assessed by 2-tailed Student t test.